AMAG Pharmaceuticals
| Public | |
| Traded as | NASDAQ: AMAG |
| Industry | Pharmaceutical Industry |
| Founded | November 9, 1981 |
| Headquarters | United States |
| Products | Pharmaceutics |
| Website |
www |
|
Footnotes / references Founded[1] | |
AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company is a publicly traded company listed on NASDAQ under the symbol "AMAG".
Operations
AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.[2]
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of US$71.5 million in 2013.[3]
In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020.[4]
Drug approvals and distribution
The company's research and tests focus on iron deficiency anemia and related intravenous drugs.[1]
In June 2009, the company's main product Ferumoxytol, an oral medication used on adult patients with chronic kidney disease, was approved by US Food and Drug Administration.
In December 2011, Health Canada approved Ferumoxytol, under the brand name Feraheme, for use in treating both dialysis and non-dialysis dependent chronic kidney disease patients, as well as for treatment of adult patients suffering from iron deficiency anemia.[5]
From 2010 to 2014, AMAG had a distribution agreement with Takeda which granted them exclusivity to the Canadian and European Union markets, where the drug is sold under the brand names Feraheme and Rienso, respectively.[6]
References
- ↑ 1.0 1.1 "AMAG Pharmaceuticals Inc (AMAG.O) company profile". Reuters. Retrieved 29 December 2014.
- ↑ "AMAG Profile". Yahoo! Finance. Retrieved 29 December 2014.
- ↑ "Amag Pharma shares tumble on FDA ruling". Yahoo! Finance. Associated Press. 22 January 2014.
- ↑ "AMAG Pharmaceuticals Announces Issuance of New U.S. Patent for Ferumoxytol" (Press release). AMAG Pharmaceuticals. 7 August 2013.
- ↑ "Health Canada Approves Feraheme® (ferumoxytol) to Treat Iron Deficiency Anemia in Adults with Chronic Kidney Disease" (Press release). AMAG Pharmaceuticals. December 2011 – via FierceBiotech.
- ↑ "AMAG Pharmaceuticals and Takeda Announce Mutual Termination of Agreement to License, Develop and Commercialize Ferumoxytol in Ex-U.S. Territories, Including Europe" (Press release). AMAG Pharmaceuticals. 29 December 2014 – via Seeking Alpha.